Covered recipient · General Payments record
PATRICIA E HAPPEL
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2019–2024
$10,508.29
- Reported across 32 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $7,593.75 | 2 |
| Travel and Lodging | $1,612.78 | 3 |
| Food and Beverage | $846.23 | 12 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $9,954.68 | 12 |
| Daiichi Sankyo Inc. | $59.47 | 3 |
| SHIELD THERAPEUTICS INC | $22.81 | 1 |
| Currax Pharmaceuticals LLC | $15.80 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Currax Pharmaceuticals LLC | $15.80 | 05/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089514308 | CMS |
| Daiichi Sankyo Inc. | $22.29 | 07/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089430880 | CMS |
| Daiichi Sankyo Inc. | $19.95 | 08/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089430884 | CMS |
| Daiichi Sankyo Inc. | $17.23 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089430882 | CMS |
| Novo Nordisk Inc | $20.62 | 02/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097619479 | CMS |
| Novo Nordisk Inc | $50.00 | 03/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097324323 | CMS |
| Novo Nordisk Inc | $87.69 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096850882 | CMS |
| Novo Nordisk Inc | $18.85 | 06/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097109945 | CMS |
| Novo Nordisk Inc | $23.24 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097410496 | CMS |
| Novo Nordisk Inc | $15.54 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097570121 | CMS |
| Novo Nordisk Inc | $562.50 | 09/24/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1096574088 | CMS |
| Novo Nordisk Inc | $7,031.25 | 09/25/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1096861554 | CMS |
| Novo Nordisk Inc | $592.28 | 09/25/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1097492437 | CMS |
| Novo Nordisk Inc | $532.21 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097693953 | CMS |
| Novo Nordisk Inc | $626.21 | 09/25/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1097733666 | CMS |
| Novo Nordisk Inc | $394.29 | 09/25/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1097838572 | CMS |
| SHIELD THERAPEUTICS INC | $22.81 | 07/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150137749 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.